PDS Biotechnology Corporation Price & Performance (PDSB)

PDS Biotechnology will present new preclinical data on its Infectimune-based influenza vaccine at the upcoming IMMUNOLOGY2025 meeting. The findings highlight broad immune responses, supporting the company’s ambition for a universal flu vaccine. This move underscores PDS Biotech’s expanding focus beyond oncology into infectious disease prevention.123

PDS Biotechnology has initiated the VERSATILE-003 Phase 3 trial for its Versamune HPV immunotherapy in HPV16-positive head and neck cancer. The FDA Fast Track-designated study aims to enroll 350 patients. Recent clinical progress and a strong cash position have contributed to improved investor sentiment and reduced short interest.435

H.C. Wainwright has lowered its price target for PDS Biotechnology stock to $13, citing ongoing losses but acknowledging better-than-expected earnings and reduced operating expenses in 2024. Despite a sharp stock decline over the past year, analysts maintain a Buy rating, reflecting confidence in the company’s clinical pipeline.657